Content Type: Article

  • A win for telehealth providers, health plans, and participants: HDHP telehealth safe harbor permanently reinstated

    A win for telehealth providers, health plans, and participants: HDHP telehealth safe harbor permanently reinstated

    ARTICLE / CLIENT ALERT

    A win for telehealth providers, health plans, and participants: HDHP telehealth safe harbor permanently reinstated

    July 18, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On July 4, 2025, the president signed the One Big Beautiful Bill Act (H.R. 1) into law. Among many other healthcare provisions, the bill permanently extends the telehealth safe harbor for high-deductible health plans (HDHPs) for plan years beginning after December 31, 2024. The permanent telehealth safe harbor is a big win for telehealth providers, health plans, and participants, many of whom advocated for its reinstatement to provide telehealth services at low or no cost to HDHP participants. The telehealth HDHP safe harbor expands access to telehealth and other remote care services for millions of individuals and dependents who are covered by HDHPs, which are often the lowest cost and most popular of the coverage options that employer-sponsored group health plans offer.

    The previous safe harbor temporarily permitted HDHPs to cover telehealth and remote care services on a first-dollar basis without jeopardizing eligibility for health savings account contributions through December 31, 2024. After months of negotiations and advocacy from digital health and employer groups, the permanent extension was included in the bill and made retroactive. This means there was no interruption in the safe harbor, and HDHPs may continue covering these services without cost-sharing.

    As a result of the permanent extension of the telehealth HDHP safe harbor, digital health and telehealth providers, virtual and remote care providers, employer plan sponsors, insurers, and third-party administrators may reassess and update their services and coverage for HDHP participants. For example, employer plan sponsors may elect to reinstate free or low-cost coverage for telehealth services retroactively to January 1, 2025, or choose to do so prospectively for the next plan year, if at all. Telehealth providers, insurers, and third-party administrators may wish to work with their employer and health plan partners to update their services and plan administration to reflect the potential increase in demand for telehealth and remote care services from HDHP participants, who can now access these services with no cost-sharing prior to satisfying the applicable deductible.

    For more information or to discuss how the permanent telehealth HDHP safe harbor impacts your organization, contact the authors of this article or your regular M+ or McDermott contact.

    In depth
    Authors

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • Proposals For Relaxation of EU Securitization Framework

    Proposals For Relaxation of EU Securitization Framework

    ARTICLE / CLIENT ALERT

    Proposals For Relaxation of EU Securitization Framework

    July 18, 2025

    Read time: 10 min

    Key takeaways
    Overview

    Vlad Maly and Michal Chajdukowski present the key takeaways from a package of amendments to the existing EU securitization framework, published by the European Commission on June 17, 2025.

    The proposals aim at incentivizing EU banks to engage in more securitization activity. The goal is to strengthen the banks’ lending capacity, which is needed to finance strategic EU priorities, including in the defense sector. Among other things, the Commission proposes to simplify due diligence and transparency requirements, introduce greater risk sensitivity, and address the perceived overcapitalization requirements that apply to investments in certain securitization exposures.

    While the impact of these measures on reviving the EU securitization markets remains uncertain (even in the eyes of EU financial authorities), the European Commission is not stopping there, announcing additional measures designed to incentivize insurers and certain retail funds to invest in securitization transactions, that are expected to be published in the coming weeks.

    In depth

    Background

    The current EU securitization framework (set out in Regulation (EU) 2017/2402 (the “Securitization Regulation”), Regulation (EU) 575/2013 (the “CRR”) and corresponding delegated acts) finds its origins in the Global Financial Crisis of 2008, which revealed how securitization (traditionally considered to have a positive impact on financial markets due to its ability to increase liquidity and lending capacity of the banks) may significantly challenge the stability of the financial system when not properly regulated.

    To address this risk, the EU introduced stringent rules applicable to transactions falling within the following definition of ‘securitization’ under the Securitization Regulation

    “‘securiti[z]ation’ means a transaction or scheme, whereby the credit risk associated with an exposure or a pool of exposures is tranched, having all of the following characteristics:

    (a) payments in the transaction or scheme are dependent upon the performance of the exposure or of the pool of exposures;

    (b) the subordination of tranches determines the distribution of losses during the ongoing life of the transaction or scheme;

    (c) the transaction or scheme does not create exposures which possess all of the characteristics listed in Article 147(8) of [the CRR].”

    The parties involved in these transactions must comply with the risk retention, transparency, and due diligence requirements set out in the Securitization Regulation. In addition, the CRR requires the participating banks to hold an increased amount of capital for their securitization exposures.

    However, this regime has been criticized on numerous occasions for being overly conservative and hindering the development of the EU securitization markets. Of particular concern are high operational costs for issuers and investors required to comply with the requirements under the Securitization Regulation, and undue prudential barriers for banks and insurers investing in securitizations.

    The amendments proposed by the Commission respond to the most recent calls for amendments, such as those included in the report of Mario Draghi (former President of the European Central Bank), who considered the change of the securitization framework an important step towards strengthening the lending capacity of EU banks needed in the context of new EU defense priorities.

    Relaxation proposals

    The proposals are not an overhaul of the regime, but rather a series of targeted amendments aimed at relaxing the existing rules under the Securitization Regulation (without repealing its core elements) and lowering capital requirements for banks involved in securitizations under the CRR.

    The main aspects of the proposals are:

    • Due Diligence

    Currently, prior to investing in a securitization, investors are required to conduct a set of prescribed verifications regarding compliance by the originator, sponsor, or original lender, as relevant, with the Securitization Regulation.

    The amendments propose to remove this requirement whenever (i) the sell-side party is established and supervised in the EU, or (ii) multilateral development banks fully guarantee the securitization position. In addition, the requirements will be reduced where the securitization includes a first-loss tranche (representing at least 15% of the nominal value of the securitized exposures) that is guaranteed or held by certain public entities.

    • Risk Retention

    As of now, the originator, sponsor or original lender, as relevant, is required to retain on an ongoing basis a material net economic interest in the securitization of not less than 5%. The amendments propose to waive this requirement for securitizations guaranteed or held by certain public entities.

    • Reporting

    Under the current regime, the originator, sponsor or a securitization special purpose vehicle must provide specific information to investors, regulators and, upon request, potential investors. The templates for such reporting are published, but do not differentiate between public and private securitizations. The amendments propose to simplify the existing templates by removing at least 35% of fields and creating a new, lighter template for private securitizations.

    The proposals define a ‘public securitization’ as follows:

    “a securiti[z]ation that meets any of the following criteria:

    (a) a prospectus has to be drawn up for that securiti[z]ation pursuant to Article 3 of Regulation (EU) 2017/1129 [the EU Prospectus Regulation];

    (b) the securiti[z]ation is marketed with notes constituting securiti[z]ation positions admitted to trading on a Union trading venue as defined in Article 4(1), point (24) of Directive 2014/65/EU [MiFID II]

    (c) the securiti[z]ation is marketed to investors and the terms and conditions are not negotiable among the parties.” (emphasis added)

    A ‘private securitization’ is defined as a securitization that does not meet any of the above criteria.

    • STS Securitizations

    The Securitization Regulation introduced a specific framework for ‘simple, transparent, and standardized’ (“STS”) securitizations, allowing the involved banks to comply with lower capital requirements compared to non-STS securitizations. As of now, for a securitization to qualify as an STS one, 100% of its underlying pool of exposures must consist of loans granted to small and medium-sized enterprises (“SME”). The amendments propose to lower this requirement to 75%, thereby opening the framework to mixed securitizations (with exposure of up to 25% to non-SME loans).

    In addition, the proposals extend the scope of eligibility criteria for credit protections for the STS securitizations to also cover unfunded guarantees issued by certain insurance or reinsurance companies.

    • Capital Requirements

    Currently, banks must apply specific fixed ‘risk weight floors’ when calculating the capital they are required to hold against their securitization exposures: 10% against the exposure to a senior position of STS securitization, and 15% against the exposure to a senior position of non-STS securitization. The amendments propose to introduce a new concept of a ‘risk-sensitive risk weight floor’ calculated with regard to the riskiness of the underlying pool of exposures. This would allow the concerned banks to apply lower floors than currently required.

    Further, the proposals introduce changes to the ‘(p) factor,’ one of the parameters used in the formulae for calculating securitization risk weights. The (p) factor determines an additional amount of capital that banks are required to hold against their securitization positions, compared to the capital they would need to hold if the underlying exposures were not securitized. The current method of calculating this parameter is considered by some market participants to result in arguably excessive and unjustified levels of overcapitalization for certain securitizations. The amendments address this issue by recalibrating the (p) factor, allowing banks to benefit from reduced capital requirements for investments in senior positions, originator/sponsor positions, and STS securitizations. The formulae are also adjusted to neutralize differences between the (p) factor levels calculated under the SEC-IRBA and SEC-SA formula-based approaches. The risk weight tables under the external rating-based approach (SEC-ERBA) would be amended accordingly to reflect these reductions.

    Finally, a new concept of ‘resilient securitization positions’ will be introduced, allowing banks involved in low-risk securitizations (regarding agency and model risks, as well as robust loss-absorbing capacity) to benefit from additional reductions in capital requirements.

    Insurers and UCITS Funds

    The Commission is currently working on two other proposals. The first of them, expected to be published in the coming weeks, is a set of rules aimed at removing unnecessary prudential costs for insurers investing in securitizations.

    The second one, still being considered by the European Commission, would allow retail funds established under Directive 2009/65/EC [the UCITS Directive] to invest more than 10% in a single securitization issuance. However, no details have yet been provided on what the new limits would be.

    Comment

    Relaxation of the existing rules is definitely welcomed by the EU securitization community. Whether these measures will actually provide a second life to EU securitization markets is a more complex question. Back in 2022, the European Supervisory Authorities (comprising the European Banking Authority, the European Insurance and Occupational Pensions Authority and the European Securities and Markets Authority) stressed that “the impact that may come from the targeted relaxation of the bank capital requirements is […] likely to be relatively small when looking at the securiti[z]ation market as a whole.” Most recently, during the debate at the European Parliament’s Committee on Economic and Monetary Affairs on July 15, 2025, Claudia Buch, the Chair of the European Central Bank’s Supervisory Board, stated that she does “not see how securitization will help […] increase access to equity finance [and] to finance long-term investments.”

    In the same vein, the Impact Assessment Report published with the proposals argues that a number of external factors providing EU banks with cheaper funding alternatives might have disincentivized them from engaging in securitizations. Relevant factors mentioned in this context include accommodative monetary policy with easily available central bank funding (up until 2022), stable deposits, and liquid EU covered bond markets. That said, it remains to be seen how the proposals will impact the markets in the current less-favourable macroeconomic context.

    What is definitely missing in the published documents is the discussion on non-Securitization Regulation securitizations. The analysis behind the amendments solely focuses on in-scope securitizations (i.e., those involving tranching), 80% of which, according to the European Commission, occur in only 5 EU Member States (France, Germany, Italy, the Netherlands, and Spain), while ignoring a significant and thriving market of non-tranche securitization. In this regard, the Commission seems to overlook a number of bespoke regimes, such as Luxembourg. No proposals have been put forward on how to reconcile, harmonize or, at least, address these co-existing regimes.

    What would also be welcomed are clarifications on the ‘sole purpose’ regime (relevant for determining which entity qualifies as an originator for the purposes of the risk retention requirements), particularly in connection with a more flexible equivalent implemented in the UK last year. Without doubt, these proposals clearly mark another step leading to further divergence between the EU and UK regimes (read our client alert on the new UK securitization rules).

    Timing

    The proposals now need to pass through the EU legislative process. This will entail review by the European Parliament and the Council of the EU. Multiple modifications and versions of the proposed amendments may be therefore expected. Once the final texts are voted on by both the Council and the Parliament and published in the Official Journal of the EU, an 18-month transition period would usually apply before they fully enter into force.

    Authors

    Vlad Maly

    Partner

    London – 22 Bishopsgate

    More insights

  • State court action doesn’t create reasonable apprehension of related federal claims

    State court action doesn’t create reasonable apprehension of related federal claims

    ARTICLE

    State court action doesn’t create reasonable apprehension of related federal claims

    Jul 17, 2025

    Read time: 4 min

    Key takeaways
    Overview

    Addressing whether a federal district court had jurisdiction over an action for declaratory relief that certain trade secrets and trademarks were invalid and not infringed, the US Court of Appeals for the Eighth Circuit concluded that state law claims for breach of contract, trade secret misappropriation, and trademark infringement did not create a reasonable apprehension of federal litigation sufficient to give rise to federal jurisdiction. Thunderhead of Ankeny, Inc. v. Chicken Bones of Kearney, Inc., Case No. 24-2741 (8th Cir. July 8, 2025) (Colloton, Arnold, Gruender, JJ.)

    Nearly 20 years ago, David Anders sold his equity in Chicken Bones of Kearney, Inc., which ran a bar and grill called the Chicken Coop. Anders subsequently opened a new Chicken Coop restaurant. Chicken Bones sued Anders for misappropriating Chicken Bones’ trade secrets, trademarks, and trade dress. The parties settled, and Anders received a limited license to the Chicken Coop intellectual property. Anders then opened several other Chicken Coop locations under that license.

    Believing that Anders had not complied with the license in opening the new restaurants, Chicken Bones sued Anders in state court for breach of the settlement agreement, misappropriation of trade secret recipes, and infringement of the Chicken Coop trademarks and trade dress. In response, Anders sued Chicken Bones in federal court, seeking declarations of noninfringement and invalidity. The district court dismissed the suit for lack of jurisdiction. Anders appealed.

    The parties and the Eighth Circuit assumed that the district court would have jurisdiction only if the suit presented a federal question. The Eighth Circuit explained that to assess federal question jurisdiction in the case of a declaratory action, the Court must imagine a traditional action that presents the same controversy and determine whether a federal claim would appear on the face of the resulting complaint. “If, but for the availability of the declaratory judgment procedure, the federal claim would arise only as a defense to a state created action, jurisdiction is lacking.”

    Applying this principle, the Eighth Circuit concluded that the district court did not have jurisdiction over Anders’ declaratory action because he primarily sought vindication of his defenses to Chicken Bones’ pending state law claims. While the Court recognized that Anders also sought declaratory relief in anticipation of potential federal trade secret, trademark, and trade dress claims, the Court reasoned that any federal law controversy between the parties was too speculative to support jurisdiction. While a threat of litigation can give rise to a justiciable controversy, there was no evidence that Chicken Bones would assert overlapping and duplicative federal law claims against Anders. The Eighth Circuit further found that Chicken Bones’ petition to cancel Anders’ federal trademark registration of a Chicken Coop logo did not change its analysis, because the petition merely confirmed the existence of a trademark infringement dispute between the parties, which Chicken Coop elected to adjudicate in state court.

    The Eighth Circuit distinguished cases involving state law trade secret claims concerning a patented invention. Because there is no state patent system, such trade secret claims can give rise to a reasonable apprehension of federal patent litigation and provide a “jurisdictional hook for a preemptive declaratory judgment action in federal court.” By contrast, trade secret and trademark claims can be based on federal or state law, so the court must look to context to determine whether there is a justiciable federal dispute. Because context indicated that Chicken Bones would pursue state law remedies alone, the only justiciable controversy arose under state law.

    Authors
    More insights
    Endnotes

  • FDA teases faster approval times with new agency-wide AI tool

    FDA teases faster approval times with new agency-wide AI tool

    ARTICLE / CLIENT ALERT

    FDA teases faster approval times with new agency-wide AI tool

    July 17, 2025

    Read time: 4 min

    Key takeaways
    Overview

    The US Food and Drug Administration (FDA) launched Elsa, a generative artificial intelligence (AI) tool designed to assist FDA employees with tasks such as reading, writing, and summarizing. The press release on the tool’s launch states that FDA is already using the tool to accelerate clinical protocol reviews, speed up scientific evaluations, support safety profile assessments, and identify high-priority inspection targets. FDA’s May 8, 2025, announcement that it would be ramping up use of AI across all centers teased faster regulatory approvals as a result, along with a quote from FDA Commissioner Dr. Martin A. Makary stating FDA’s widespread adoption of AI “hold[s] tremendous promise in accelerating the review time for new therapies.”

    In depth

    The launch of Elsa comes less than a month after FDA Commissioner Makary directed all FDA centers to begin deploying AI, with a stated target of full integration of AI across the agency by June 30, 2025. The use of AI allows scientific-review tasks that typically take days to complete to be performed within minutes. FDA states it is already using Elsa to summarize adverse events as part of safety profile assessments, identify high-priority inspection targets, perform label comparison, speed up clinical protocol reviews, and accelerate scientific evaluations. Elsa can also generate code that can be used to help develop databases for nonclinical applications. FDA intends to evaluate further use cases for Elsa and other AI tools moving forward, with data processing and generative AI functions as an early focus.

    FDA appears confident that generative AI could allow its scientists and other experts to reduce the time spent on repetitive tasks that slow down the review process. FDA Commissioner Makary indicated that AI tools could help reduce “the amount of non-productive busywork that has historically consumed much of the review process.” Like FDA’s bid to phase out animal testing, which we previously covered, this initiative is the latest in a series of efforts at FDA that the agency claims have the potential to reduce approval times for new therapies.

    Elsa is the latest example of the agency’s willingness to engage with AI’s impact on the industry. We previously addressed two draft guidance documents released by FDA in January 2025 that address AI-enabled device software functions and the use of AI to support regulatory submissions related to drugs and biologics. These guidance documents are the latest in a series of workshops, discussion papers, and guidance on the use of AI from FDA. FDA’s focus on the technology does not appear to be waning, with FDA Commissioner Makary recently commenting that the agency will have to think creatively about how it regulates new AI technologies. Elsa demonstrates that FDA is taking this concept a step further and adopting AI within its own processes.

    Elsa is powered by large language models (LLMs) and built within a high-security GovCloud environment that FDA says allows agency staff to securely access internal documents while ensuring the data remains within the agency. According to FDA, Elsa’s models were not trained on data submitted by regulated industries.

    McDermot will continue to monitor FDA’s AI rollout and how it may impact the agency’s review times for new therapies and ongoing oversight activities for existing therapies. If you have any questions about FDA’s recent actions or about the FDA review process, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Nathan Gray

    Associate

    Washington, DC

    More insights

  • IRS roundup: June 18 – July 11, 2025

    IRS roundup: June 18 – July 11, 2025

    ARTICLE

    IRS roundup: June 18 – July 11, 2025

    Jul 15, 2025

    Read time: 6 min

    Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for June 18, 2025 – July 11, 2025.

    “One Big Beautiful Bill Act” tax provisions

    On July 4, 2025, US President Donald Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law, which enacted several changes to federal tax law. Some of the key changes that affect IRS administration and/or federal tax procedure include:

    • Form 1099-NEC reporting threshold. The reporting threshold for payments to non-employees for personal services will be raised from $600 to $2,000 beginning in 2026. While amounts below the threshold will still constitute income subject to taxation, an employer will not be subject to backup withholding requirements or be required to issue a Form 1099 if the total value of the services provided cost less than $2,000.
    • Controlled foreign corporations (CFCs). The look-through rule for CFCs under Internal Revenue Code Section 954 is permanently extended. New Section 951B extends the CFC inclusion rules to “foreign controlled US shareholders” of foreign-controlled CFCs (the US shareholder must own more than 50% by value or vote of the foreign corporation to be designated as such). The tax law also creates a one-month deferral election for determining a CFC’s tax year.
    • Opportunity zone designation. The OBBBA establishes a permanent opportunity zone policy, maintaining current designation guidelines. For investors with investments made after December 31, 2026, gains deferred via investment in the Qualified Opportunity Zone program will now be recognized on the fifth anniversary of the investment date.

    Additionally, the OBBBA introduces a detailed reporting regime as included in new Code Sections 6039K and 6039L. A penalty provision in Code Section 6726 is also included to improve oversight and transparency regarding the economic impact of qualified opportunity investments. The reporting penalties can be as high as $10,000 per return or up to $50,000 for qualified opportunity funds with assets worth more than $10 million. The US Department of the Treasury must publish annual reports on opportunity zone investments and economic performance of the designated tracts.

    • Employee Retention Credit (ERC) update. Pending ERC claims filed after January 31, 2024, for the third or fourth quarters of 2021 are disallowed under the tax law. The statute of limitations on assessment for ERC (i.e., the period during which the IRS may recapture ERC through assessment) was also extended to six years. The OBBBA also imposes penalties on ERC promoters who fail to comply with due diligence requirements and demonstrate that they did not facilitate the making of fraudulent claims.

    IRS guidance

    June 23, 2025: The IRS issued Notice 2025-30, publishing the inflation adjustment factor and reference price for calendar year 2025 for the renewable electricity production credit under Code Section 45. The inflation adjustment factor for calendar year 2025 for qualified energy resources is 1.9971, and the reference price for calendar year 2025 for facilities producing electricity from wind is 3.1 cents per kilowatt hour. The IRS has not yet issued guidance on reference prices for other renewable energy sources.

    June 30, 2025: The IRS issued Notice 2025-32 within Internal Revenue Bulletin 2025-27, updating certain tables pertaining to the enhanced oil recovery credit under Code Section 43(b). The notice includes the secretary of the Treasury’s published inflation adjustment factor used for 2025 credit determination, as well as the phase-out amount for taxable years beginning in the 2025 calendar year.

    Because the reference price for the 2024 calendar year multiplied by the inflation adjustment factor for the 2025 calendar year exceeds a certain threshold, the enhanced oil recovery credit for qualified costs paid or incurred in 2025 is phased out completely for the 2025 tax year.

    June 30, 2025: Bulletin 2025-27 highlighted more information relevant to the oil and gas industry in Notice 2025-34, which provides the applicable reference price for qualified natural gas production from qualified marginal wells during calendar year 2025. The applicable reference price for taxable years beginning in calendar year 2025 is $1.64 per 1,000 cubic feet.

    The notice also provides the credit amount used for the purpose of determining the marginal well production credit, found under Code Section 451. The credit amount for taxable years beginning in calendar year 2025 is $0.79 per 1,000 cubic feet.

    July 2, 2025: The IRS withdrew regulations under Code Section 382(h) related to built-in gain and loss, publishing the withdrawal in the Federal Register. The document withdraws two notices of proposed regulations regarding the treatment of built-in items of income, gain, deduction, and loss taken by a loss corporation after an ownership change.

    The proposed regulations in question date back to 2019 and would have adopted, as mandatory (subject to certain modifications), the safe harbor for the net unrealized built-in gain and loss computations defined in Notice 2003-65. Called the “1374 approach,” these regulations received criticism from practitioners and taxpayers, so the IRS has chosen to withdraw the regulations. While the Treasury is expected to issue a revised notice of proposed rulemaking regarding Code Section 382(h), taxpayers may continue to rely on the approaches set forth in Notice 2003-65 for applying Section 382(h) to an ownership change.

    July 7, 2025: The IRS released Internal Revenue Bulletin 2025-28. It includes information that taxpayers may use to determine whether they meet certain requirements under the Statistical Area or Coal Closure Categories as described in Sections 3.03 and 3.04 of Notice 2023-29 for purposes of qualifying for energy community bonus credit amounts or rates under Code Sections 45, 45Y, 48, and 48E.

    Bulletin 2025-28 also includes Revenue Ruling 2025-13, which posts the federal rates, adjusted federal rates, adjusted federal long-term rate, and long-term tax exempt rate. For purposes of Code Sections 382, 1274, 1288, and 7872, among other sections, the tables set forth the rates for July 2025.

    July 11, 2025: The IRS withdrew regulations under Code Section 6045 requiring certain decentralized finance industry participants to file and furnish information returns as brokers. Congress passed a joint resolution disapproving the final rule titled Gross Proceeds Reporting by Brokers that Regularly Provide Services Effectuating Digital Asset Sales, originally enacted in December 2024.

    The IRS initially provided transitional relief from the penalties for brokers who failed to report these gross proceeds correctly, as issued in Notice 2025-33 and identified in the previous IRS Roundup. However, this final regulation withdrawal makes the transitional relief permanent.

    The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice).

    Lindsay Keiser, a summer associate in the Washington, DC, office, also contributed to this blog post.

    In depth
    Authors

    Evan Walters

    Partner

    Chicago

    Edward L. Froelich

    Counsel

    Washington, DC

    Michael J. Scarduzio

    Partner

    New York – One Vanderbilt Avenue

    Samuel F. Hamer

    Associate

    Washington, DC

    More insights
    Endnotes

  • Key takeaways | Financing the energy transition: capital strategies for a changing landscape

    Key takeaways | Financing the energy transition: capital strategies for a changing landscape

    ARTICLE

    Key takeaways | Financing the energy transition: capital strategies for a changing landscape

    July 14, 2025

    Read time: 3 min

    Key takeaways
    Overview

    The Energy Transition Credit Summit 2025, held on June 2 in New York City, brought together industry leaders to discuss the rapidly evolving energy and infrastructure investment landscape. Co-hosted by McDermott Will & Emery and Fifth Third Securities, the event featured a high-impact investor panel, curated matchmaking sessions, and a networking reception. The panel featured leading voices from top-tier energy and infrastructure investment firms, including Apterra Infrastructure Capital, Brookfield Asset Management, Orion Infrastructure Capital (OIC), and Segue Sustainable Infrastructure. The following sets out the key takeaways from this esteemed panel.

    Session panelists

    • Dave Blanchard, Managing Director & Investment Principal, OIC
    • Ralph Cho, Co-Chief Executive Officer and Founding Member, Apterra Infrastructure Capital
    • Andrew Ehrlickman, Senior Vice President, Brookfield
    • Paul Hildebrand, Principal, Segue Sustainable Infrastructure
    • Chris Gladbach, Partner, McDermott Will & Emery, Moderator
    • James McGinnis, Managing Director, Fifth Third Securities, Moderator
    In depth

    Key takeaways

    Policy uncertainty and market disruption: Panelists expressed concerns over proposed legislative changes, such as the begin of construction cliff and tax credit phase-downs, which could jeopardize over $300 billion in clean energy investments. These provisions are challenging for capital-intensive projects with extended lead times.

    Data centers driving power demand: The surge in AI-driven data centers is significantly impacting power markets. Developers are focusing on areas with cheap and available power, like West Texas. Lenders highlighted the necessity of reliable grid interconnection, noting that behind-the-meter solutions currently fall short of 24/7 uptime requirements.

    Cautious innovation in financing structures: As transferability continues to gain traction, the emphasis is shifting towards finding buyers and scaling existing structures. Further, mid-market deals are particularly benefiting from creative capital stacks that traditional banks might overlook.

    Transition to IPP models: Developers are increasingly moving towards owning and operating assets due to a softening M&A market. Lenders are adapting to support these models but caution that independent power producer (IPP) strategies demand substantial capital, operational scale, and equity, posing challenges for smaller players.

    Strategic and transparent developer engagement: Lenders advised developers to engage strategically, targeting appropriate capital providers and presenting clear, straightforward models. Emphasis was placed on the quality of development pipelines over sheer quantity, with local knowledge being a critical factor.

    Authors
    More insights

  • FinCEN prohibits fund transfers involving three Mexico-based financial institutions under FEND Off Fentanyl Act

    FinCEN prohibits fund transfers involving three Mexico-based financial institutions under FEND Off Fentanyl Act

    ARTICLE / CLIENT ALERT

    FinCEN prohibits fund transfers involving three Mexico-based financial institutions under FEND Off Fentanyl Act

    July 14, 2025

    Read time: 11 min

    Key takeaways
    Overview

    On June 25, 2025, the US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued three orders (the “rders”) pursuant to 21 U.S.C. § 2313a, a recently enacted authority under the FEND Off Fentanyl Act (the “Fentanyl Act”), designating three Mexico-based financial institutions as “primary money laundering concerns” in connection with illicit opioid trafficking.[1] The institutions, which include two banks, CIBanco, S.A., Institución de Banca Múltiple (“CIBanco”) and Intercam Banco, S.A., Institución de Banca Múltiple (“Intercam”), and one brokerage firm, Vector Casa de Bolsa, S.A. de C.V. (“Vector”) (collectively, the “Designated Entities”), are alleged to have facilitated significant financial transactions on behalf of Mexico-based cartels engaged in fentanyl production and distribution.[2] The Orders mandate that any covered financial institution (“Covered Institution”) as defined under the Bank Secrecy Act (“BSA”),[3] including, but not limited to, banks, broker-dealers, money services businesses and mutual funds, must reject transactions involving the Designated Entities.[4] Investment advisers are not currently subject to the Orders, but will be on Jan. 1, 2026.

    The Orders mark the first use of Section 2313a since it was enacted in 2024, reflecting an escalation in the federal government’s efforts to, in the words of Treasury Secretary Scott Bessent, use “all tools at [its] disposal to counter the threat posed by criminal and terrorist organizations trafficking fentanyl and other narcotics.”[5] The special measures in the Fentanyl Act have similarities to special measures under Section 311 under the USA PATRIOT Act but have additional features.[6]

    The Orders are effective Sept. 4, 2025 and have no expiration date.[7] This Alert provides an overview of the Orders, including background information, a summary of findings, and an analysis of compliance obligations and considerations. Additionally, it outlines potential penalties and highlights recent developments, offering guidance on preparatory actions for compliance in leading up to the effective date.

    Background

    Since President Trump’s return to office in January 2025, the executive branch has prioritized disrupting international narcotics trafficking, with a focus on fentanyl and other synthetic opioids. Early in 2025, President Trump signed an Executive Order that established a framework for designating certain drug cartels as Foreign Terrorist Organizations or Specially Designated Global Terrorists.[8] Under these authorities, the Departments of State and Treasury designated eight organizations, some of which FinCEN alleges dealt with the Designated Entities, including the Sinaloa Cartel, the Jalisco New Generation Cartel (“CJNG”) and the Gulf Cartel.[9]

    Separately, Congress passed the Fentanyl Act in 2024. The Fentanyl Act included 21 U.S.C. § 2313a, which empowers the Secretary of the Treasury to impose targeted obligations or restrictions on US financial institutions where it determines, “upon reasonable grounds,” that a foreign financial institution, transaction or account is of “primary money laundering concern” in connection with illicit opioid trafficking.[10] Upon such a determination, the statute allows the Secretary to require US financial institutions to comply with one or more “special measures.”[11] The special measures available under § 2313a include those also authorized under Section 311 of the USA PATRIOT Act, as well as the ability to prohibit or impose conditions on the transfer of funds to or from the designated party.[12]

    Unlike Section 311, which broadly addresses money laundering threats and requires special measures via rulemaking with a notice-and-comment period, § 2313a targets opioid-related trafficking and allows FinCEN to swiftly impose special measures by order, without notice and comment.[13]

    Summary of the Orders

    Scope

    The Orders target the Mexico-based operations of the Designated Entities, prohibiting transactions to and from these entities, including their branches, subsidiaries and offices within Mexico.[14] The Orders prohibit “transmittals of funds from or to” the Designated Entities “or from or to any account or convertible virtual currency address administered by or on behalf of” the Designated Entities.[15] The Orders do not affect the Designated Entities branches and offices outside of Mexico, including those in the United States. They also do not apply to any other affiliates, regardless of their location, or their parent holding companies.[16] However, Covered Institutions should be careful of reputational or money laundering risks when doing business with these entities outside of Mexico.

    Findings

    The Orders assert that the Designated Entities have each played a “longstanding” and vital role in facilitating money laundering activities of Mexico-based cartels involved in illicit opioid trafficking, including laundering funds for cartels engaged in fentanyl production and distribution.[17] As a result, FinCEN designated the Designated Entities as being of “primary money laundering concern” due to their provision of financial services that aid illicit opioid trafficking by Mexico-based drug trafficking organizations.[18]

    • CIBanco. FinCEN designated CIBanco for its role in facilitating financial transactions on behalf of multiple Mexico-based cartels, including CJNG, the Gulf Cartel and the Beltrán-Leyva Organization.[19] CIBanco is alleged to have processed payments tied to the procurement of precursor chemicals from China used in fentanyl synthesis.[20] In one instance, a CIBanco employee knowingly facilitated the creation of an account to launder $10 million on behalf of a Gulf Cartel member.[21]
    • Intercam. FinCEN designated Intercam due to its involvement in facilitating transactions linked to illicit opioid trafficking.[22] FinCEN highlighted a series of meetings in late 2022 between Intercam executives and CJNG representatives, concerning the transfer of funds from China to Mexico to support cartel operations.[23] From 2021 to 2024, a Chinese company associated with precursor chemical shipments reportedly received more than $1.5 million via Intercam from Mexican counterparties.[24]
    • Vector. FinCEN designated Vector, a Mexico-based brokerage firm, as a conduit for laundering drug proceeds and financing chemical procurement by major cartels, including the Sinaloa and Gulf Cartels.[25] The Vector Order indicated that between 2013 and 2021, a Sinaloa Cartel operative used Vector to transfer approximately $2 million from the United States to Mexico.[26] Between 2018 and 2023, Vector facilitated more than $1 million in payments to Chinese companies known to be involved in the precursor chemical trade.[27] FinCEN noted in its Order that these activities reflect material weaknesses in Vector’s anti-money laundering/countering the financing of terrorism (“AML/CFT”) compliance program.[28]

    Compliance Obligations and Consideration

    Requirements for Covered Institutions

    FinCEN has issued a series of FAQs to assist with compliance. By the effective date of Sept. 4, 2025, Covered Institutions are expected to:

    • Cease engaging in fund transfers to or from the Designated Entities, including any transaction through an account or convertible virtual currency address held by or on behalf of such entities.[29] Covered Institutions must reject any prohibited fund transmittal. Notably, the Orders do not require the blocking or freezing of assets.[30]
    • Consider FinCEN’s designation of the Designated Entities as institutions of primary money laundering concern in connection with broader BSA obligations, including the requirement to establish and maintain an effective AML/CFT compliance program.[31]

    Preparatory Steps for Compliance

    FinCEN expects Covered Institutions to implement appropriate measures to comply with the Orders, including conducting reasonable due diligence to prevent direct or indirect transactions involving the Designated Entities.[32] Steps Covered Institutions can take to comply with the Orders include:

    • Implementing customer screening and transaction monitoring systems capable of identifying and rejecting transactions involving the Designated Entities.
    • Training relevant personnel, including those in customer-facing, operations and compliance roles, to ensure they are aware of the restrictions and able to identify and address prohibited transactions.
    • Reviewing client relationships, agreements and transaction flows to assess potential exposure to the Designated Entities. Covered Institutions should also evaluate contractual rights and obligations, including the ability to reject or delay fund transfers under existing agreements.
    • Assessing the impact on trust-related transactions, including situations in which a Designated Entity acts solely as trustee.
    • Following the issuance of the Orders, the Ministry of Finance and Public Credit announced that it was temporarily transferring the trusts managed by CIBanco and Intercam to Mexican development banking entities to continue their operation under the National Banking and Securities Commission’s supervision.[33] Covered Institutions should consider whether transitioning the trustee to alternative financial institutions may be appropriate, particularly in the context of evolving regulatory guidance.

    Importantly, the Orders do not contain an exception for future or contingent payment obligations under agreements entered into before their issuance. Any transfer of funds to or from a Designated Entity on or after September 4, 2025 is prohibited. While the Orders contain no exemptions for specific transactions, FinCEN retains the authority to grant specific exceptions or authorizations on a case-by-case basis.

    Compliance Questions Raised

    The Orders do not, by themselves, impose new suspicious activity reporting (“SAR”) obligations when a Covered Institution rejects a prohibited fund transmittal.[34] FinCEN has advised that, consistent with existing BSA obligations, Covered Institutions should assess whether transactions involving a Designated Entity warrant the filing of a SAR based on the facts and circumstances.[35] In cases where a SAR is filed, Covered Institutions should include relevant customer and transactional information, such as names, identification numbers, contact details, and a detailed description of the activity, and use the applicable identifier in Field 2 of the SAR form: “CIBanco2313a FIN 2025,” “Intercam2313a FIN 2025” or “Vector2313a FIN 2025.”[36]

    Although the Orders do not restrict correspondent accounts and therefore do not require standard USA PATRIOT Act Section 311-style notices to foreign correspondent account holders, Covered Institutions should be mindful of elevated risk. Furthermore, the compliance implications of the Orders may extend beyond Covered Institutions currently covered by the BSA. By explicitly linking the Designated Entities to Mexican drug trafficking organizations designated as foreign-terrorist organization (“FTO”), FinCEN’s actions may expose counterparties to legal and reputational risks. These include increased scrutiny for potential involvement in money laundering or narcotics trafficking, and potential exposure under US counterterrorism laws, including the material support statute, which prohibits knowingly providing “material support or resources” to an FTO.[37] For example, a company engaged in business with a Designated Entity could come under scrutiny for indirectly facilitating the activities of a designated cartel by transacting through a Covered Institution. Companies should therefore reevaluate their compliance programs and strengthen due diligence controls to identify potential exposure to high-risk counterparties. In particular, firms should closely monitor FinCEN advisories, such as the June 2024 guidance addressing fentanyl precursor chemicals and manufacturing equipment and reassess their indirect risk exposure where foreign banks maintain correspondent relationships with the Designated Entities.[38]

    Penalties

    Violations of an Order can lead to civil and criminal liability for a Covered Institution, as well as its directors, officers, and employees. If a Covered Institution violates an Order, FinCEN may impose a civil money penalty of at least two times the amount of the transaction but not exceeding $1,776,364 (adjusted for inflation).[39] If a Covered Institution willfully violates the Orders, it may be subject to a criminal fine of at least two times the amount of the transaction but not exceeding $1,000,000.[40]

    Prospective Future Developments

    The legal and political situation remains dynamic. Mexican President Claudia Sheinbaum has challenged the allegations behind FinCEN’s designations, asserting that the Treasury Department has failed to provide any evidence of money laundering, despite the Mexican government’s repeated requests. Sheinbaum noted that Mexican investigations into CIBanco, Intercam Banco and Vector revealed no wrongdoing and emphasized that the Designated Entities conduct legitimate transactions with established Chinese companies in Mexico.[41] Meanwhile, in response to the Orders, Mexico’s banking regulator, the Comisión Nacional Bancaria y de Valores (“CNBV”), has intervened in CIBanco and Intercam to safeguard the rights of savers and customers, placing management decisions under the CNBV’s direct supervision.[42] Additionally, as these Orders mark Treasury’s inaugural use of its authority under the Fentanyl Act, it may face legal or political challenges from the Designated Entities or the Mexican Government.

    Conclusion

    Treasury’s designation of the Designated Entities as primary money laundering concerns highlights its priority to combat drug trafficking, especially involving illicit opioids. The government is expected to continue leveraging these authorities to address drug trafficking and related threats. In today’s shifting legal and political landscape, Covered Institutions must establish up-to-date compliance frameworks and carefully monitor transactions and relationships with potentially sanctioned entities to effectively meet BSA obligations. Schulte Roth & Zabel advises clients to implement robust due diligence and compliance strategies to mitigate exposure to regulatory penalties and reputational risks.

    Authored by Betty Santangelo, Melissa G.R. Goldstein, Kyle B. Hendrix, Hannah Thibideau, and Julianna R. Pasquarello.

    If you have any questions concerning this Alert, please contact your lawyer at McDermott Will & Schulte or one of the authors.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    Julianna R. Pasquarello

    Associate

    New York – 919 Third Avenue

    More insights

  • 2024 Benchmark Survey of Financial Services Transactions Between US Financial Services Providers and Foreign Persons (Form BE-180) – Due July 31, 2025

    2024 Benchmark Survey of Financial Services Transactions Between US Financial Services Providers and Foreign Persons (Form BE-180) – Due July 31, 2025

    ARTICLE / CLIENT ALERT

    2024 Benchmark Survey of Financial Services Transactions Between US Financial Services Providers and Foreign Persons (Form BE-180) – Due July 31, 2025

    July 11, 2025

    Read time: 4 min

    Key takeaways
    Overview

    The US Department of Commerce’s Bureau of Economic Analysis (the “BEA”) collects information on international trade in services and direct investment. Every five years, the BEA collects the BE-180 Survey of Financial Services Transactions Between US Financial Services Providers and Foreign Persons (“BE-180”). The BE-180 survey is required from all US persons who have engaged in any covered financial services transactions during fiscal year 2024, including US investment managers with non-US clients and non-US investment managers with US-domiciled funds.

    BE-180 surveys are due no later than July 31, 2025. Extensions may be requested by contacting the BEA at be-180extension@bea.gov.[1]Reporting requirements apply regardless of whether a US person has been contacted by the BEA.

    US “financial service providers,” including US-domiciled fund managers and US-domiciled funds (as well as other US-domiciled financial services providers, such as banks and broker-dealers), are required to submit a BE-180 if they engaged in any financial services transactions with foreign persons in 2024. Of particular note for our private fund manager clients, BE-180 surveys are required where, during fiscal year 2024:

    • a US-domiciled investment manager received fees, incentive allocations or carried interest from a non-US fund or managed account (including non-US funds sponsored by the US investment manager or its affiliates); or
    • a US-domiciled fund or person paid a non-US investment manager fees, incentive allocations or carried interest (including US funds sponsored by the non-US investment manager or its affiliates).

    Payment and/or receipt of fees, incentive allocations or carried interest is determined on an accrual basis and is reportable on BE-180 in connection with discretionary or non-discretionary investment management and/or advisory activities.

    The examples of covered financial services mentioned here are of specific interest to our private fund manager clients; however, a range of additional cross-border purchases of, or sales by, US persons of financial services are covered by the BE-180 survey and would trigger reporting. Covered services include, for example: brokerage, underwriting and private placement, credit-related activities, financial custody, proxy advisory, securities lending, electronic funds transfer, and “other” services (e.g., crypto wallet fees, asset pricing, securities or futures clearing and settlement services).

    There is no de minimis exemption from the requirement to file the BE-180 survey; however, US reporters may submit a truncated version of BE-180 surveys if they had, during fiscal year 2024:

    • combined purchases of covered financial services from non-US persons that were less than or equal to $3 million; and
    • combined sales of covered financial services to non-US persons that were less than or equal to $3 million.

    Many fund managers currently submit a quarterly companion survey, BE-185, which covers many of the same transactions as BE-180; however, filing BE-185 does not exempt a US reporter from submitting a BE-180 survey, even if the information included is substantially similar.

    Find information on the BE-180 survey, including copies of the survey, instructions and instructional videos.

    If you would like to discuss any aspect of the BE-180 surveys, please contact Christopher S. Avellaneda, Kara A. Kuchar or your usual Schulte contact.


    [1] Reports can be submitted electronically at www.bea.gov/efile. Reports may also be submitted via fax to (301) 278-9508 or mail to: Bureau of Economic Analysis Balance of Payments Division, BE-50 (SSB) 4600 Silver Hill Rd., Washington, DC 20233.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Christopher S. Avellaneda

    Partner

    New York – 919 Third Avenue

    More insights

  • SEC hosts roundtable on executive compensation disclosure requirements

    SEC hosts roundtable on executive compensation disclosure requirements

    ARTICLE / CLIENT ALERT

    SEC hosts roundtable on executive compensation disclosure requirements

    July 9, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On June 26, 2025, the US Securities and Exchange Commission (SEC) hosted a roundtable attended by issuers, institutional investors, third-party advisors, and industry groups to discuss potential updates to current executive compensation disclosure requirements.

    In depth

    Introductory remarks by SEC Chair Paul Atkins set the tone for the three SEC representatives in attendance, with Chair Atkins referring to the current disclosure regime as a “Frankenstein patchwork of rules” and SEC Commissioner Hester Peirce drawing a comparison between the current disclosure requirements and a focus on “random trees at the expense of a realistic view of the forest.” At the root of the roundtable was a question posited by Chair Atkins in a statement issued in advance: Has the increased complexity and length of executive compensation disclosures provided investors with additional information that is material to their investment and voting decisions?

    Topics discussed covered the gamut of disclosures required under Item 402 of Regulation S-K, including the Summary Compensation Table (SCT), other tabular disclosures, and the Compensation Discussion and Analysis narrative disclosures, as well as rules implemented in the wake of the Dodd-Frank Act of 2010, such as the introduction of mandatory Say-on-Pay proposals, pay versus performance (PvP) and CEO pay ratio disclosures, and the recently finalized clawback rules. While the debate was lively, there appeared to be a broad consensus that the current disclosure framework warrants meaningful reevaluation in light of considerations such as the direct costs associated with the ever-growing list of disclosure requirements, externalities arising from the potential distortion of corporate behavior in response to various mandates, and other deficiencies.

    The three topics that received the most attention from moderators and panelists alike included two Dodd-Frank mandates (the PvP and CEO pay ratio disclosures) and the classification of personal executive security expenses as a “perquisite.” Absent a few dissenting voices, participants generally took the position that the perceived benefits of the current PvP and CEO pay ratio disclosures are outweighed by the significant costs incurred in satisfying the disclosure requirements. Several panelists representing both issuers and investors pushed back at the classification of personal security as a perquisite warranting disclosure in the SCT. However, panelists appeared open to the concept of disclosure of personal security benefits, provided such perquisite was not a component of Named Executive Officer pay in the SCT.

    Given that many of the disclosures discussed during the roundtable are mandated by statute, including PvP, CEO pay ratio, and the clawback rules, it is somewhat unlikely that meaningful reforms will follow in the near term. The SEC can, however, provide updated guidance on perquisite disclosure, as current disclosure standards generally arise from existing SEC guidance and not law. Chair Atkins framed the roundtable as “one of the first steps” in reevaluating the current executive compensation disclosure regime. The SEC is soliciting public comments as part of this reevaluation, which can be submitted in paper, email, or electronically.

    Authors

    Craig Garvey

    Partner

    Chicago

    Kate Vera Coverdale

    Partner

    New York – One Vanderbilt Avenue

    Galen Spielman

    Associate

    Austin

    More insights

  • Florida expands rules favoring noncompetes while other states limit them further

    Florida expands rules favoring noncompetes while other states limit them further

    ARTICLE / CLIENT ALERT

    Florida expands rules favoring noncompetes while other states limit them further

    July 8, 2025

    Read time: 7 min

    Key takeaways
    Overview

    2025 has been a busy year for new state legislation on employee restrictive covenant agreements, particularly in the healthcare sector. While several states have pushed forward new legislation restricting employee restrictive covenant agreements, Florida bucks the trend.

    This patchwork of state-specific laws creates a complex landscape for employers, making it increasingly challenging to navigate and comply with the varying regulations across different states. For businesses operating in multiple states, this can mean significant legal and operational hurdles, as they must tailor their employment contracts and practices to meet the unique requirements of each jurisdiction. Despite these challenges, understanding and adapting to these changes is crucial for maintaining compliance and protecting business interests.

    In depth

    Florida

    While most states have moved to further limit noncompete agreements, the Sunshine State took a clear step in the opposite direction when the Florida Contracts Honoring Opportunity, Investment, Confidentiality, and Economic Growth Act (dubbed the “CHOICE Act”) went into effect on July 1, 2025.

    The CHOICE Act applies to employees who earn a salary that is the greater of either twice the annual median wage (i) of the Florida county in which the employer has its principal place of business or (ii) where the employee or contractor resides, if the employer’s principal place of business is outside of Florida. (Note: the CHOICE Act does not apply to “health care practitioners” as defined in Section 456.001 of the Florida statutes). Chapter 542 of the Florida statutes already contains a comprehensive set of rules favoring enforceability of noncompetes so long as they are reasonable in time, duration, and scope. The CHOICE Act mostly supplements this existing structure by allowing employers to restrict competition in two respects:

    • Under a covered garden leave agreement, an employer may use a “garden leave” arrangement to effectively terminate an employee but retain them long enough to prevent them from joining a competitor. Under this arrangement, the employee is not required to perform any work for the employer and still receives the same salary and benefits for up to four years in exchange for the employee’s promise not to work for another employer without employer approval. The post-employment period under a garden leave agreement is often referred to as the “notice” period.
    • Under a covered noncompete agreement, an employer may use a noncompete agreement lasting no more than four years to restrict a former employee from working for a competitor. This is a slight change from Chapter 542, which provides that an employment-related noncompete (versus a sale-of-business noncompete) is presumptively unreasonable if it lasts more than two years.

    For both sets of agreements, the CHOICE Act requires certain prerequisites for enforceability. Namely, they both must be in writing and advise the employee of the right to counsel with at least seven days to review the agreement before signing, and the employee must acknowledge in writing that they received confidential information or were responsible for substantial client relationships during the term of their employment.

    A covered garden leave agreement must also state that (i) the employee does not have to work beyond the first 90 days of the notice period; (ii) the employee may engage in non-work activities during the remainder of the notice period; (iii) the employee may work for another employer with the employer’s permission during the notice period; and (iv) the notice period may be reduced if the employer provides at least 30 days’ advanced notice in writing.

    A covered noncompete agreement must additionally state that the noncompete duration is reduced day-for-day by any non-working portion of a covered garden agreement’s notice period. Essentially, if an employer requires an employee to sign both a noncompete and a garden leave agreement, the noncompete must specifically state that its duration is reduced by the overlapping days between the noncompete and the garden leave agreement.

    To enforce these agreements, the CHOICE Act makes it easier for employers to seek injunctive relief; courts must issue an injunction unless the employee can demonstrate by clear and convincing evidence that the agreement does not apply or the employer failed to pay consideration for the agreement.

    Employers expecting to enter into noncompete agreements, particularly with healthcare employees, should work with counsel to understand the state-specific limitations and requirements.

    Maryland

    Maryland House Bill 1388 (HB 1388), which went into effect on July 1, 2025, bans noncompetes with certain healthcare workers and limits such agreements under specific circumstances.

    • The law voids noncompetes entered into on or after July 1, 2025, with healthcare professionals earning $350,000 per year or less.
    • The law restricts noncompetes entered into on or after July 1, 2025, with healthcare professionals earning more than $350,000 to a duration of one-year post-employment and a 10-mile radius from the professional’s primary place of employment. The law does not define the “primary place of employment.”
    • Employers must provide the new location of a former employee if a patient requests it.
    • Healthcare professionals, for the purposes of this law, include anyone required to be licensed under the Health Occupations Article who is employed in a position that provides direct patient care.

    Texas

    The Lone Star State amended certain provisions of the Texas Business and Commerce Code to narrow the scope of enforceable noncompete agreements against certain medical practitioners. The new law, effective September 1, 2025, applies to physicians licensed by the Texas Medical Board and certain “healthcare practitioners” (specifically licensed dentists, vocational nurses, and physician assistants).

    One physician-specific limitation is that noncompetes can only be enforced against licensed physicians that are terminated for good cause. The law defines good cause as “a reasonable basis for discharge of a physician from contract or employment that is directly related to the physician’s conduct, including the physician’s conduct on the job or otherwise, job performance, and contract or employment record.” The new law also carves out “managing or directing medical services in an administrative capacity for a medical practice or other healthcare provider” from the definition of the “practice of medicine,” meaning that noncompetes against those in a managerial position are likely not subject to the new law’s requirements.

    Any noncompete must be in clear writing and provide for a “buy out” that is no greater than the practitioner’s total annual salary and wages at the time of termination. Prior Texas law provided that the buy out must be at a “reasonable price.”

    As for scope, the new law states that an enforceable restrictive covenant (i) cannot last more than one year and (ii) must be limited to a radius of no greater than five miles from where the practitioner “primarily practiced” before termination.

    Nevada

    Nevada Senate Bill 378 (NV SB378) was delivered to Governor Joe Lombardo on June 5, 2025, but was vetoed and sent back the legislature. If enacted, the law would have banned noncompetes entered into by any employee who is a “patient-facing provider of health care,” which is defined to include any provider (i) whose primary duties involve providing clinical care to patients and (ii) who is not employed or contracted to primarily perform administrative tasks.

    *****

    Employers expecting to enter into noncompete agreements, particularly with healthcare employees, should work with counsel to understand the state-specific limitations and requirements. McDermott will continue to monitor developments in this rapidly changing area of the law.

    Authors

    Brian Mead

    Partner

    Chicago

    Jean Edmonds

    Associate

    Chicago

    More insights